Chris has over 25 years’ experience across pharmaceutical sciences and biopharmaceutics. His current role at Quotient involves designing science-led, robust, clinical study programs which maximise output for clients, in addition to providing scientific leadership throughout study delivery. He has a specific interest and responsibility at Quotient for studies which involve scintigraphic imaging. Prior to Quotient, Chris held a series of technical and leadership roles at Sanofi, Pfizer, AstraZeneca and Walgreens Boots Alliance. His experience ranges from early pre formulation and biopharmaceutical assessments, through development of a wide range of dosage forms from the pre-clinical phase up to life-cycle management of marketed products.